PHAT vs WVE
PHAT: Phathom Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal diseases, anchored by its potassium-competitive acid blocker platform. WVE: Wave Life Sciences is a clinical-stage biotech company developing stereopure nucleic acid therapeutics via its proprietary PRISM platform to treat genetically defined diseases.
Side-by-side fundamentals
| Metric | PHAT | WVE | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $8.75 | $5.51 | |
| Market cap as of 2026-08-03 | $708M | $1.1B | |
| PEG as of 2026-08-03 | n/a | -0.11 | |
| Net margin as of 2026-08-03 | -76.8% | -255.7% | PHAT higher |
| Gross margin as of 2026-08-03 | +84.9% | n/a | |
| Operating margin as of 2026-08-03 | -47.5% | -274.2% | PHAT higher |
| ROE as of 2026-08-03 | -232.8% | -55.7% | WVE higher |
| ROA as of 2026-08-03 | -59.7% | -42.8% | WVE higher |
| Debt / equity as of 2026-08-03 | 12.38 | 0.00 | WVE lower |
| Revenue growth (YoY) as of 2026-08-03 | +150.3% | -31.6% | PHAT higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +127.1% | |
| Beta as of 2026-08-03 | 1.11 | 1.48 | |
| 1-year return as of 2026-07-31 close | +2.5% | -32.0% | PHAT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.